English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma

Satzger, I., Marks, L., Kerick, M., Klages, S., Berking, C., Herbst, R., et al. (2015). Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. Oncotarget, 2015: 5634. doi:10.18632/oncotarget.5634.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0028-EC0D-A Version Permalink: http://hdl.handle.net/11858/00-001M-0000-0028-EC12-9
Genre: Journal Article

Files

show Files
hide Files
:
Satzger.pdf (Publisher version), 2MB
Name:
Satzger.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
@ 2015 Impact Journals, LLC
License:
-

Locators

show

Creators

show
hide
 Creators:
Satzger, Imke , Author
Marks, Lena, Author
Kerick, Martin1, Author              
Klages, Sven1, Author              
Berking, Carola , Author
Herbst, Rudolf, Author
Völker, Bernward , Author
Schacht, Vivien , Author
Timmermann, Bernd1, Author              
Gutzmer, Ralf , Author
Affiliations:
1Sequencing (Head: Bernd Timmermann), Scientific Service (Head: Christoph Krukenkamp), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_1479670              

Content

show
hide
Free keywords: metastatic melanoma, primary melanoma, BRAFV600 mutation, BRAF inhibitor
 Abstract: Background: The detection of BRAFV600 mutations in patients with metastatic melanoma is important because of the availability of BRAF inhibitor therapy. However, the clinical relevance of the frequency of BRAFV600 mutant alleles is unclear. Patients and Methods: Allele frequencies of BRAFV600 mutations were analyzed byultra-deepnext-generation sequencing in formalin-fixed, paraffin-embedded melanoma tissue (75 primary melanomas and 88 matched metastases). In a second study, pretreatment specimens from 76 patients who received BRAF inhibitors were retrospectively analyzed, and BRAFV600 allele frequencies were correlated with therapeutic results. Results: Thirty-five patients had concordantly BRAF-positive and 36 (48%) patients had concordantly BRAF-negative primary melanomas and matched metastases, and four patients had discordant samples with low allele frequencies (3.4–5.2%). Twenty-six of 35 patients with concordant samples had BRAFV600E mutations, three of whom had additional mutations (V600K in two patients and V600R in one) and nine patients had exclusively non-V600E mutations (V600K in eight patients and V600E -c.1799_1800TG > AA- in one patient). The frequency of mutated BRAFV600 alleles was similar in the primary melanoma and matched metastasis in 27/35 patients, but differed by >3-fold in 8/35 of samples. BRAFV600E allele frequencies in pretreatment tumor specimens were not significantly correlated with treatment outcomes in 76 patients with metastatic melanoma who were treated with BRAF inhibitors. Conclusions: BRAFV600 mutation status and allele frequency is consistent in the majority of primary melanomas and matched metastases. A small subgroup of patients has double mutations. BRAFV600 allele frequencies are not correlated with the response to BRAF inhibitors.

Details

show
hide
Language(s): eng - English
 Dates: 2015-10-062015-10-16
 Publication Status: Published online
 Pages: 11
 Publishing info: -
 Table of Contents: -
 Rev. Method: -
 Identifiers: DOI: 10.18632/oncotarget.5634
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Oncotarget
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 2015 Sequence Number: 5634 Start / End Page: - Identifier: ISSN: 1949-2553 (Online)